drugset
drugset / Trial / NCT04023331

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

NCT04023331 ↗

Phase 1/2 Terminated 21 enrolled Clarity Pharmaceuticals Ltd
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Timeline

Start
2020-08-18
Primary completion
2025-01-24
Completion
2025-03-25

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject 67Cu-SARTATE Unknown — Intravenous
Background 64Cu-SARTATE Diagnostic / imaging agent 2 mbq/kg —

Indications

neuroblastoma